Pfizer Inc Income Statement Quarterly
PFE
|
Select the Financial Report: |
Period: |
Fiscal Year: |
|
|
|
|
INCOME STATEMENT
(Quarterly GAAP In millions $) |
(Jun 30 2024)
II. Quarter |
(Mar 31 2024)
I. Quarter |
(Dec 31 2023)
IV. Quarter |
(Oct 01 2023)
III. Quarter |
(Jul 02 2023)
II. Quarter |
| Revenue From Contract With Customer Excluding Assessed Tax |
10,871.00 |
12,443.00 |
|
- |
- |
| Revenue From Contract With Customer Excluding Assessed Tax |
- |
- |
|
- |
- |
| Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer |
2,067.00 |
2,172.00 |
|
- |
- |
| Other Revenue |
345.00 |
264.00 |
|
- |
- |
| Total Revenue |
13,283.00 |
14,879.00 |
14,248.00 |
13,232.00 |
12,734.00 |
| Cost of Goods and Services Sold |
3,300.00 |
3,379.00 |
7,562.00 |
9,269.00 |
3,237.00 |
| Gross
Profit |
9,983.00 |
11,500.00 |
6,686.00 |
3,963.00 |
9,497.00 |
| Selling, Administration, Marketing |
3,717.00 |
3,495.00 |
4,575.00 |
3,281.00 |
3,497.00 |
| Depriciation & Amortization |
1,307.00 |
1,308.00 |
1,267.00 |
1,179.00 |
1,184.00 |
| Research & development |
2,696.00 |
2,493.00 |
2,815.00 |
2,711.00 |
2,648.00 |
| Restructuring Charges AndAcquisition Related Costs |
1,254.00 |
102.00 |
2,565.00 |
155.00 |
214.00 |
| Other exp. /-income |
- |
- |
- |
- |
- |
| Special Items |
- |
- |
- |
- |
- |
| Total operating costs including COS |
12,274.00 |
10,777.00 |
18,784.00 |
16,595.00 |
10,780.00 |
| Operating income/-loss
|
1,009.00 |
4,102.00 |
-4,536.00 |
-3,363.00 |
1,954.00 |
|
Other Deductions / - Income |
| Interest expense |
- |
- |
- |
- |
- |
| Interest income |
- |
- |
- |
- |
- |
| Net interest expense/-income |
- |
- |
- |
- |
- |
| Loss/ -Gain on Investment |
- |
- |
- |
- |
- |
| Income from affiliates |
- |
- |
- |
- |
- |
| Minority interest |
- |
- |
- |
- |
- |
| Financing Loss/ -Income |
- |
- |
- |
- |
- |
| Other loss/ -income |
1,112.00 |
681.00 |
-407.00 |
-11.00 |
-315.00 |
| Total costs & expenses |
13,386.00 |
11,458.00 |
18,377.00 |
16,584.00 |
10,465.00 |
| Income /-loss before income taxes |
-103.00 |
3,421.00 |
-4,129.00 |
-3,352.00 |
2,269.00 |
| Income taxes expenses/-benefit |
-134.00 |
293.00 |
-795.00 |
-964.00 |
-71.00 |
| Income after income taxes |
31.00 |
3,128.00 |
-3,335.00 |
-2,388.00 |
2,340.00 |
| Net income/-loss
of other equity |
- |
- |
- |
- |
- |
| Income/-loss
from cont. Ops. |
31.00 |
3,128.00 |
-3,334.00 |
-2,388.00 |
2,340.00 |
| Accounting change |
- |
- |
- |
- |
- |
| Discontinued operations |
17.00 |
-5.00 |
-26.00 |
12.00 |
-2.00 |
| Extraordinary items |
- |
- |
- |
- |
- |
| Net Income/-loss |
48.00 |
3,123.00 |
-3,360.00 |
-2,376.00 |
2,338.00 |
| Noncontrolling interests |
7.00 |
8.00 |
9.00 |
6.00 |
11.00 |
| Prefered dividends |
- |
- |
- |
- |
- |
| Other |
- |
- |
- |
- |
- |
| Income/-loss to shareholder |
41.00 |
3,115.00 |
-3,369.00 |
-2,382.00 |
2,327.00 |
| EBIT |
-103.00 |
3,421.00 |
-4,129.00 |
-3,352.00 |
2,269.00 |
| EBITD |
1,628.00 |
5,157.00 |
-2,459.00 |
-1,792.00 |
3,842.00 |
| EBITDA |
1,628.00 |
5,157.00 |
-2,459.00 |
-1,792.00 |
3,842.00 |
| Per
Share (GAAP Quarterly, in $) |
(Jun 30 2024)
II. Quarter |
(Mar 31 2024)
I. Quarter |
(Dec 31 2023)
IV. Quarter |
(Oct 01 2023)
III. Quarter |
(Jul 02 2023)
II. Quarter |
| Basic EPS (excl. extra
items) |
0.01 |
0.55 |
-0.59 |
-0.42 |
0.41 |
| Extraordinary items |
0.00 |
0.00 |
0.01 |
0.00 |
0.00 |
| Basic Net EPS |
0.01 |
0.55 |
-0.60 |
-0.42 |
0.41 |
| Basic shares outstanding (Mill.
of Units) |
5,666.00 |
5,657.00 |
5,646.00 |
5,646.00 |
5,646.00 |
| EPS other shares |
- |
- |
- |
- |
- |
| Diluted Net EPS |
0.01 |
0.55 |
-0.59 |
-0.42 |
0.41 |
| Diluted average shares (Mill.
of Units) |
5,696.00 |
5,697.00 |
5,727.03 |
5,646.00 |
5,713.00 |
| Dividend per share |
0.418 |
0.416 |
0.404 |
0.41 |
0.405 |
|
|
